Actively Recruiting
Open-label Study to Assess Pharmacokinetics, Safety, and Tolerability of AX251 Long-Acting Injectable in Adults with Schizophrenia
Led by Anxo Pharmaceutical Co., Ltd. · Updated on 2026-09-16
48
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the pharmacokinetics, safety, and tolerability of AX251 long-acting injectable LAI given as a single dose in adults with schizophrenia. The study focuses on different dose levels of AX251 LAI through sequential dose-escalation groups to understand how the drug is processed and tolerated. It is a Phase 1, open-label, multicenter trial sponsored by Anxo Pharmaceutical Co., Ltd. Participants will receive one of four doses of AX251 LAI45 mg, 90 mg, 135 mg, or 180 mgin separate groups. The study is non-randomized and does not use blinding. Each participant will receive a single injection of the assigned dose and be monitored over time. There are no placebo groups, and the primary treatment period involves only one dose administration. During the study, participants will be closely monitored with blood sampling for pharmacokinetic measurements at multiple times from immediately before dosing up to 70 days after injection. Safety will be assessed by tracking adverse events from baseline through Day 70. Participants must stay at the study site for 7 days after dosing for observation and will undergo clinical evaluations, including physical exams, ECGs, and laboratory tests. The total participation lasts about 10 weeks, focusing on safety and drug behavior in the body.
CONDITIONS
Brief Title
Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia
Research Team
M
Mico Hsu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here